1RODRIGUEZ-BANO J, CISNEROS J M, FERNANDEZ- CUENCA G, et al. Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospital [ J ]. Infect Control Hosp Epidemiol, 2004, 25(10) :819-824.
2ROSENTHAL V D, MAKI D G, JAMULITRAT S, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009 [ J ]. Am J Infect Control, 2010, 38 ( 2 ) : 95-104.
3GORDON N C, WAREHAM D W. Muhidrug-resistant Aci- netobacter baumannii: mechanisms of virulence and resistance [ J ]. Int J Antimicrob Agents, 2010, 35 ( 3 ) : 219-226.
4COYNE S, ROSENFELD N, LAMBERT T, et al. Overex- pression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in Acinetobacter baumannii [ J ]. Antimicrob Agents Chemother, 2010, 54 (10) :4389-4393.
5WASAZNIK A, GRINHOLC M, BIELAWSKI K P. Active efflux as the muhidrug resistance mechanism [ J ]. Postepy Hig Med Dosw, 2009, 63:123-133.
6OPAZO A C, MELLA S M, DOMINGUEZ M Y, et al. Multi-drug efflux pumps and antibiotic resistance in Acinetobacter baumannii [ J ]. Rev Chilena Infectol , 2009, 26(6) :499-503.
7MARTI S, FERNANDEZ-CUENCA F, PASCUAL A, et al. Prevalence of the tetA and tetB genes as mechanisms of resistance to tetracycline and minocycline in Acinetobacter baumannii clinical isolates [ J ]. Enferm Infect Microbiol Clin, 2006, 24(2):77-80.
8RIBERA A, ROCA I, RUIZ J, et al. Partial charac- terization of a transposon containing the tet (A) determinant in a clinical isolate of Acinetobacter baumannii [ J ]. J Antimicrob Chemother, 2003, 52 (3):477-480.
9ESWARAN J, KORONAKIS E, HIGGINS M K, et al. Three's company:component structures bring a closer view of tripartite drug effiux pumps [ J ]. Curr Opin Struct Biol, 2004, 14(6) :741.
10PELEG A Y, ADAMS J, PATERSON D L. Tigecycline efflux as a mechanism for nonsusccptibility in Acinetobacter baumannii[ J ]. Antimicrob Agents Chemother, 2007, 51 (6) :2055-2059.
3Bergogne-Berezin E, Towner K J. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features [J]. Clin Microbiol Rev, 1996,9 (2) : 148-165.
4Falagas M E, Bliziotis I A. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era.'? [J]. Int J Antimicrob Agents, 2007,29 (6) : 630- 636.
5Piddock L J V. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria [J]. Clin Microbiol Rev, 2006,19 (2) : 382 - 402.
6Li X Z, Nikaido H. Efflux-mediated drug resistance in bacteria [J]. Drugs,2004,64(2) : 159-204.
7Magnet S, Courvalin P, Lambert T. Resistance-nodula- tion-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454 [J]. Antimicrob Agents Chemother, 2001,45 (12) : 3375-3380.
8Marehand I, Piolle DL, Courvalin P, et al. Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system [J]. Antimicrob Agents Chemother, 2004, 48 (8) : 3298-3304.
9Chau S L, Chu Y W, Houang E T. Novel resistancenodulation-cell division efflux system AdeDE in Acineto- bacter genomic DNA group 3 [J]. Antimicrob Agents Chemother, 2004,48 (10) : 4054- 4055.
10Chu Y W, Chau S L, Houang E T. Presence of active efflux systems AdeABC, AdeDE and AdeXYZ in different Acinetobacter genomic DNA groups [J]. J Med Microbiol, 2006,55 (4) : 477-478.
